{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?sponsor=Inotek+Pharmaceuticals+Corporation",
    "query": {
      "sponsor": "Inotek Pharmaceuticals Corporation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-10-08T08:06:11.604Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01123785",
      "title": "A Dose-Escalation Study Designed to Evaluate the Tolerability, Safety, Pharmacokinetics (PK), and Efficacy of Chronic Topical Ocular Application of INO-8875 in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "INO-8875",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "77 Years",
        "sex": "ALL",
        "summary": "18 Years to 77 Years"
      },
      "enrollment_count": 144,
      "start_date": "2010-05",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-10-15",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01123785"
    },
    {
      "nct_id": "NCT00271167",
      "title": "A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Heart Diseases",
        "Postoperative Complications"
      ],
      "interventions": [
        {
          "name": "INO-1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 162,
      "start_date": "2005-10",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2015-03-25",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 5,
      "location_summary": "Boston, Massachusetts • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Rapid City",
          "state": "South Dakota"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00271167"
    },
    {
      "nct_id": "NCT02829996",
      "title": "Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "trabodenoson 6.0% / latanoprost 0.005% QD",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 3.0% / latanoprost 0.005% QD",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 6.0% / latanoprost 0.0025% QD",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.005% QD",
          "type": "DRUG"
        },
        {
          "name": "latanoprost 0.0025% QD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2016-08-19",
      "completion_date": "2017-05-31",
      "has_results": true,
      "last_update_posted_date": "2018-02-15",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 1,
      "location_summary": "Lexington, Massachusetts",
      "locations": [
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02829996"
    },
    {
      "nct_id": "NCT00271765",
      "title": "A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myocardial Infarction"
      ],
      "interventions": [
        {
          "name": "INO-1001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2004-01",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2006-11-29",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 10,
      "location_summary": "Fort Lauderdale, Florida • Valparaiso, Indiana • Saint Paul, Minnesota + 7 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Valparaiso",
          "state": "Indiana"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Newark",
          "state": "New Jersey"
        },
        {
          "city": "Toledo",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00271765"
    },
    {
      "nct_id": "NCT01123772",
      "title": "Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Health"
      ],
      "interventions": [
        {
          "name": "INO-8875",
          "type": "DRUG"
        },
        {
          "name": "Placebo control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 70,
      "start_date": "2010-05",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2012-04-30",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 1,
      "location_summary": "Evansville, Indiana",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01123772"
    },
    {
      "nct_id": "NCT01917383",
      "title": "A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "Trabodenoson",
          "type": "DRUG"
        },
        {
          "name": "Latanoprost",
          "type": "DRUG"
        },
        {
          "name": "Timolol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2013-08",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 1,
      "location_summary": "Bristol, Tennessee",
      "locations": [
        {
          "city": "Bristol",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01917383"
    },
    {
      "nct_id": "NCT02565173",
      "title": "Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Open-Angle Glaucoma (POAG)",
        "Ocular Hypertension (OHT)"
      ],
      "interventions": [
        {
          "name": "trabodenoson 4.5% BID",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 6.0% QD",
          "type": "DRUG"
        },
        {
          "name": "trabodenoson 3.0% QD",
          "type": "DRUG"
        },
        {
          "name": "timolol 0.5% BID",
          "type": "DRUG"
        },
        {
          "name": "placebo BID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Inotek Pharmaceuticals Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 303,
      "start_date": "2015-09",
      "completion_date": "2016-11",
      "has_results": false,
      "last_update_posted_date": "2016-12-06",
      "last_synced_at": "2026-10-08T08:06:11.604Z",
      "location_count": 1,
      "location_summary": "Lexington, Massachusetts",
      "locations": [
        {
          "city": "Lexington",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02565173"
    }
  ]
}